Trial Details

Brief Summary

The purpose of this study is to look for low levels of oxygen (hypoxia) in lung cancer using a positron emission tomography (PET) scan. Hypoxia can influence how lung cancer grows and responds to treatments like radiotherapy and chemotherapy. The use of PET scans to measure hypoxia may be better and simpler than the approaches used previously. This study will assess whether or not PET scans can provide useful information about hypoxia in lung cancer. In this study, a radiotracer called Fluoroazomycin Arabinoside (FAZA) will be used to measure hypoxia in the patient's tumour. FAZA has already been used in many cancers including lung cancer. Patients who consent to participate in this trial will receive 1 FAZA PET Scan prior to their first radiotherapy treatment

Official Title

A Feasibility Study of Hypoxia Imaging in Patients With Lung Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)

Selection Criteria

Eligibility Inclusion Criteria

Age ≥ 18 years
Patients with stage II or III lung cancer (both NSCLC and SCLC) qualifying for radiotherapy to the primary tumor, with or without treatment of mediastinal or hilar lymph nodes
Intention to treat using radiotherapy according to the current treatment policies of the PMH Lung Group
Concurrent systemic therapy allowed
A negative serum pregnancy test within the two week interval immediately prior to PET-CT imaging, in women of child-bearing age
Ability to provide written informed consent to participate in the study

Eligibility Exclusion Criteria

Previous radiotherapy to intended treatment volumes.
Previous systemic therapy
Active malignancy other than lung cancer
Unable to remain supine for more than 60 minutes
Pregnancy
Age less than 18 years old
Failure to provide written informed consent